Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01111162 · ClinicalTrials.gov registry record · Phase 4
H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT01111162: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT01111162 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01111162, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
The overall goal of this study is to study influenza vaccine responses in HIV infected individuals. Immunocompromised individuals require special protection from influenza, but may not respond appropriately to the standard killed vaccine. Patients who receive the H1N1 flu vaccine as part of their standard of care will be asked to donate blood samples for immunologic studies. These studies will determine whether participants were able to produce the appropriate antibodies to the vaccine and possibly identify predictors of vaccine responsiveness. Our hypothesis is that vaccine responsiveness to the new H1N1 influenza vaccine will be compromised in HIV infected patients.
Interventions
- BIOLOGICAL H1N1 vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01111162
The ClinicalTrials.gov registry entry for NCT01111162 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which H1N1 vaccination is the first listed.
NCT01111162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01111162 about?
NCT01111162 is a clinical study titled "H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients". The overall goal of this study is to study influenza vaccine responses in HIV infected individuals. Immunocompromised individuals require special protection from influenza, but may not respond appropriately to the standard killed vaccine. Patients who receive the H1N1 flu vaccine as part of their st...
What is the current status of trial NCT01111162?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2009-12. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01111162?
The interventions under investigation include: H1N1 vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT01111162?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.